I hereby certify that this correspondence is being deposited with the United Stafes Services on the date set forth below as First Class Mail in an envelope addressed Commissioner for Patents, Washington, D.C. 20231.

Date of Signature

November 20, 2002 and Deposit:_

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Hector F. DeLuca

Serial No.:

10/074,102

Filed:

February 12, 2002

For:

PREPARATIONS AND USE OF AN AH RECEPTOR

LIGAND, 2-(1'H-INDOLE-3'-CARBONYL)-THIAZOLE-4-

CARBOXYLIC ACID METHYL ESTER

Group Art Unit:

1645

Examiner:

Commissioner For Patents Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Enclosed is a completed Form PTO-1449 listing documents that the applicants in the above-identified application wish to bring to the attention of the Examiner for consideration in connection with the examination on the merits of this application.

No fee is believed due in connection with this submission. However, if a fee is due, please charge the fee to Deposit Account No. 17-0055.

Respectfully submitted,

Hector F. DeLuca

November 20, 2002

Zhibin Ren

Reg. No. 47,897

Quarles & Brady LLP

411 East Wisconsin Avenue Milwaukee, WI 53202-4497

(414) 277-5709

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

Complete if Known				
Application Number	10/074,102			
Filing Date	February 12, 2002			
First Named Inventor	Hector F. DeLuca			
Group Art Unit	1645			
Examiner Name				
Attorney Docket Number	960296.97206			

U.S. PATENT DOCUMENTS							
Examiner Initials	Cite No.1	U.S. Patent Number	Document Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		6,323,228		BaMaung, et al.	11/27/01		
					+		
ļ							
						RECEIVED	
						NOV 2 6 2002	
						TECH CENTER 1600/2900	
						IEUH CENTEN 1000/2000	
		 					
-	-						
	Ш.	<u> </u>		<u> </u>	<u> </u>		

	FOREIGN PATENT DOCUMENTS								
	Cite	F	oreign Patent Do			Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant	Т6	
Examiner Initials		Office ³	Number ⁴	Kind Code ⁵ (if known)			Passages or Relevant Figures Appear		
								1 1	
-		 							
		1							
		 							
		 							

Examiner	Date	
	Considere	ed
Signature		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Sheet

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE of a collection of information unless it contains a valid OMB control number.

rwork Reduction Act of 1995, no persons are required to respond to a Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449B/PTO

Application Number 10/074,102 February 12, 2002 Filing Date First Named Inventor Hector F. DeLuca Group Art Unit 1645 **Examiner Name**

(use as many sheets as necessary)

Attorney Docket Number 960296.97206

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	1
Examiner nitials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Adachi, J. et al. "Indirubin and indigo are potent aryl hydrocarbon receptor ligand present in human urine". J. Biol. Chem. 276(34):31475-31478 (2001).	
		Chen, I., Safe, S., and Bjeldanes, L. "Indole-3-carbinol and diindolylmethane as aryl hydrocarbon (Ah) receptor agonists and antagonists in T47D human breast cancer cells". Biochem. Pharmacol. 51(8):1069-1076 (1996).	
,		Chen, Y. Het al. "Regulation of CYP1A1 by indolo[3,2-b]carbazole in murine hepatoma cells". J. Biol. Chem. 270(38):22548-22555 (1995).	
		Cheung, Y. L., Snelling, J., Mohammed, N. N. D., Gray, T. J. B., and loannides, C. "Interaction with the aromatic hydrocarbon receptor, cyp1a induction, and mutagenicity of a series of diaminotoluenes - implications for their carcinogenicity". Toxicol. Appl. Pharmacol. 139(1):203-211 (1996).	
<u> </u>		Garrison, P.M. et al. "Species-specific recombinant cell lines as bioassay systems for the detection of 2,3,7,8-tetrachlorodibenzo-p-dioxin-like chemicals," Fund. Appl. Toxicol. 30:194-203 (1996).	
		Heathpagliuso, S. et al. "Activation of the Ah receptor by tryptophan and tryptophan metabolites". Biochem. 37(33):11508-11515 (1998).	
· · · · · ·		Lee, I. J. et al. "Transcriptional induction of the cytochrome p4501a1 gene by a thiazolium compound, yh439". Mol. Pharmacol. 49(6):980-988 (1996).	
		Liu, R. M.et al. "Regulation of [Ah] gene battery enzymes and glutathione levels by 5,10-dihydroindeno[1,2-b]indole in mouse hepatoma cell lines". Carcinogenesis. 15(10):2347-2352. (1994).	
		Poellinger, L. "Mechanistic aspects-the dioxin (aryl hydrocarbon) receptor". Food Add. Contam. 17(4):261-266 (2000).	
		Poland, A. and Glover, E. "Chlorinated dibenzo-p-dioxin: Potent inducers ofaminolevulinic acid synthetase and aryl hydrocarbon hydroxylase. II. A study of the structure-activity relationship". Mol. Pharmacol. 9:736-747 (1973).	
		Rannung, A. et al. "Certain photooxidized derivatives of tryptophan bind with very high affinity to the Ah receptor and are likely to be endogenous signal substances," J. Biol. Chem. 262:15422-15427 (1987).	

	Data	
Examiner	Date	
Signature	Considered	J

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE revork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitu	ute for form 1449B/PTC)		Complete if Known			
				Application Number	10/074,102		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	February 12, 2002		
				First Named Inventor	Hector F. DeLuca		
				Group Art Unit	1645		
	(use as many s	heet	s as necessary)	Examiner Name			
Sheet	3	of	3	Attorney Docket Number	960296.97206		

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
		Schaldach, C. M., Riby, J., and Bjeldanes, L. F "Lipoxin A(4): A new class of ligand for the Ah receptor". Biochem. 38(23):7594-7600 (1999).	
		Sinal, C. J. and Bend, J. R. "Aryl hydrocarbon receptor-dependent induction of cyp1a1 by bilirubin in mouse hepatoma hepa 1c1c7 cells". Mol. Pharmacol. 52(4):590-599 (1997)	
		Stephensen, P. U. et al. "N-methoxyindole-3-carbinol is a more efficient inducer of cytochrome P-450 1A1 in cultured cells than indol-3-carbinol". Nutr Cancer Internatl. J. 36(1):112-121 (2000).	
		Vasiliou, V., Shertzer, H. G., Liu, R. M., Sainsbury, M., and Nebert, D. W. "Response of [Ah] battery genes to compounds that protect against menadione toxicity". Biochem. Pharmacol. 50(11):1885-1891 (1995).	
		Washburn, B. S. et al. "Brevetoxin-6 (pbtx-6), a nonaromatic marine neurotoxin, is a ligand of the aryl hydrocarbon receptor". Arc. Biochem. Biophy. 343(2):149-156 (1997).	
		Whitlock, J.P., Jr., "Genetic and molecular aspects of 2,3,7,8-tetrachlorodibenzo-p-dioxin action," Ann. Rev. Pharmacol. Toxicol. 30:251-277 (1990).	,
		RECEIVED	
		NOV 2 6 2002	
		TECH CENTER 1600/2	900

1	Examiner		Date	
ı	Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.